Multiple Myeloma: Is it time to rethink how we sequence treatments?

Karthik Ramasamy is a Consultant Haematologist at Oxford University Hospitals NHS Trust and Associate Professor of Haematology, Radcliffe Department of Medicine, Oxford UK. Dr Ramasamy is the Director of the Oxford Myeloma Translational Research Centre, and a Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Cancer Alliance Group. He is the Divisional Lead for Cancer research for National Institute for Health Research, Clinical Research Network Thames Valley and South Midlands, UK. He is an executive member of the UK Myeloma Forum and is an active member of UK Myeloma Research Alliance. Karthik serves on the Myeloma UK Board, a patient charity exclusively dealing with myeloma advocacy and research. Dr Ramasamy completed his haematology training in London. Following this, he completed three years as a clinical research fellow working on bone marrow microenvironment in myeloma at King’s College London. Dr Ramasamy is a Chief Investigator of myeloma studies and his translational research interests are early diagnosis of myeloma, myeloma renal, bone disease and myeloma drug resistance mechanisms. Karthik has published over 50 papers and authored textbooks/ chapters on myeloma

Joshua Richter, M.D., is an Associate Professor in the Myeloma Division at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and the Director of Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai.  He completed undergraduate work at Johns Hopkins University and subsequently went on to medical school at New York Medical College. He completed residency at St. Vincent’s Hospital – New York Medical College.  Dr Richter completed his hematology/oncology fellowship at the Yale Cancer Center.  After completing fellowship he worked in the myeloma division at the John Theurer Cancer Center at Hackensack University Medical.  In 2018 he joined the Myeloma Division at Mount Sinai Hospital.   Dr Richter has been published in numerous oncology journals including NEJM, Blood, and the Journal of Clinical Oncology.   He has an interest in immunotherapy, multi-functional antibodies and precision medicine.

Consultant Haematologist at Cambridge University Hospitals NHS Foundation Trust specialising in multiple myeloma, acute leukaemia and stem cell transplantation / cellular therapy

Dr Andrew Charlton is a Consultant Haematologist at the Northern Centre for Cancer Care where he has a particular interest in myeloma treatment, apheresis medicine and transfusion, and NHS Blood and Transplant.

Dr Charlton trained in the Northern Deanery as a Registrar and then worked at the Northern Centre for Cancer Care as a Clinical Fellow in the Haemato-Oncology Clinical Trials Team.

He has a strong interest in developing the clinical trials portfolio at the Trust and was awarded NIHR ‘Greenshoots’ funding. He is Clinical Lead for Transfusion and part of the Sub-Regional Immunoglobulin Assessment Panel. He is an examiner for the FRCPath examination.